Clinical Trial: A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease

Brief Summary: To evaluate the safety and tolerability of pimavanserin over 52 weeks of treatment in subjects with probable AD who have symptoms of agitation and aggression

Detailed Summary:
Sponsor: ACADIA Pharmaceuticals Inc.

Current Primary Outcome: Safety and tolerability of pimavanserin over 52 weeks of treatment (e.g., Summary of Treatment-Emergent Adverse Events [Safety and Tolerability]) [ Time Frame: Approximately 52 weeks ]

Safety and tolerability of pimavanserin over 52 weeks of treatment in subjects with probable AD who have symptoms of agitation and aggression


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: ACADIA Pharmaceuticals Inc.

Dates:
Date Received: April 12, 2017
Date Started: February 23, 2017
Date Completion: June 2020
Last Updated: April 17, 2017
Last Verified: April 2017